C-reactive protein-to-lymphocyte ratio is a novel biomarker for predicting the long-term efficacy of ustekinumab treatment in ulcerative colitis

Ustekinumab, a new anti-interleukin-12/23 antibody, is an effective treatment for ulcerative colitis; however, data regarding predictive factors of its efficacy are limited. Predicting treatment efficacy in advance would be useful for selecting a therapeutic agent. This study aimed to identify bioma...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PloS one 2024-08, Vol.19 (8), p.e0305324
Hauptverfasser:	Koshiba, Ryoji, Kakimoto, Kazuki, Mizuta, Noboru, Numa, Keijiro, Kinoshita, Naohiko, Nakazawa, Kei, Hirata, Yuki, Miyazaki, Takako, Higuchi, Kazuhide, Nakamura, Shiro, Nishikawa, Hiroki
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Biology and Life Sciences Biomarkers Biomarkers - blood C-reactive protein C-Reactive Protein - analysis C-Reactive Protein - metabolism Care and treatment Clinical medicine Colitis, Ulcerative - blood Colitis, Ulcerative - drug therapy Effectiveness Endoscopy Female Health aspects Health services Humans Inflammatory bowel disease Interleukin 12 Lymphocyte Count Lymphocytes Lymphocytes - metabolism Male Materials selection Medical materials Medicine and Health Sciences Middle Aged Monoclonal antibodies Patients Pharmacology Physiological aspects Prognosis Proteins Remission Remission (Medicine) Remission Induction Response rates Retrospective Studies Steroids Survival analysis Treatment Outcome Tumor necrosis factor-TNF Ulcerative colitis Ustekinumab - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!